Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTH | P32929 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22273330 | 0.82 | CTH (0.44) | CTHRARBL3MBTL1ALDH1A1 | |
| SCHEMBL21533466 | 0.82 | CTH (0.39) | CTHRARBALDH1A1 | |
| SCHEMBL8380277 | 0.79 | CTH (0.37) | CTHRARBALDH1A1 | |
| SCHEMBL20669613 | 0.79 | CTH (0.37) | CTHRARBL3MBTL1ALDH1A1MAPT | |
| SCHEMBL14573902 | 0.77 | RARB (0.32) | CTHRARBL3MBTL1 | |
| SCHEMBL24086439 | 0.77 | CTH (0.36) | CTHRARB | |
| SCHEMBL14994696 | 0.73 | EPHX2 (0.34) | CTHRARBALDH1A1 | |
| SCHEMBL84552 | 0.71 | — | — | |
| SCHEMBL20915371 | 0.70 | PLA2G2A (0.40) | ALDH1A1 | |
| SCHEMBL20915198 | 0.70 | PLA2G2A (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 422 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2023-11-30 | — | — | US | disclosed |
| US-20230382912-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-30 | — | — | US | disclosed |
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2023-11-30 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11814381-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-14 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
| US-20080004282-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20070249608-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070054884-A1 | 4-SUBSTITUTED 2-ARYLOXYPHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054884-A1 | 4-SUBSTITUTED 2-ARYLOXYPHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070043021-A1 | derivatives of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine for modulating sleep disorder; side effect reduction | HYPNION, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070015716-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | HYPNION, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043021-A1 | derivatives of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine for modulating sleep disorder; side effect reduction | GABRB3, GRIN2C, GABRB2 | CTH 958/4885RARB 791/4885L3MBTL1 2252/4885 |
| US-20070249680-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | CTH 2952/4885RARB 2233/4885L3MBTL1 1001/4885 |
| US-20070004752-A1 | Benzisoxazole piperazine compounds and methods of use thereof | GABRA5, HCRTR2, HCRTR1 | CTH 1373/4885RARB 1283/4885L3MBTL1 4536/4885 |
| US-20070249608-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | CTH 2952/4885RARB 2233/4885L3MBTL1 1001/4885 |
| US-20070015716-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | SLC10A2, ABCB11, SLC10A1 | CTH 2800/4885RARB 1003/4885L3MBTL1 4711/4885 |
| US-20230382912-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | CTH 4442/4885RARB 3521/4885L3MBTL1 4611/4885 |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | CTH 966/4885RARB 2037/4885L3MBTL1 4083/4885 |
| US-20080004282-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | CTH 1076/4885RARB 3983/4885L3MBTL1 3391/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | CTH 1185/4885RARB 2339/4885L3MBTL1 4399/4885 |
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | CTH 253/4885RARB 3394/4885L3MBTL1 2418/4885 |
| US-11814381-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | CTH 4244/4885RARB 3567/4885L3MBTL1 3353/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | CTH 3317/4885RARB 539/4885L3MBTL1 4465/4885 |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | LTB4R, LTB4R2, CYSLTR1 | CTH 1022/4885RARB 901/4885L3MBTL1 4095/4885 |
| US-20070054884-A1 | 4-SUBSTITUTED 2-ARYLOXYPHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | CLPP, TYR, MRPL21 | CTH 4858/4885RARB 1408/4885L3MBTL1 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.